J1557 Gammaplex IVIG Reimbursement & Policy | OpenPayer

Summary & Overview

HCPCS J1557: Immune Globulin (Gammaplex) IV, 500 mg

HCPCS Level II code J1557 designates a 500 mg unit of intravenous immune globulin Gammaplex in a liquid form. This code is significant nationally for reporting the medication component of immune globulin therapy across outpatient infusion settings. Accurate use of J1557 affects medication billing, inventory tracking, and payer reimbursement for high-cost biologic therapies administered intravenously.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how J1557 is applied across common infusion sites, and what stakeholders typically monitor when evaluating claims with this code.

Readers will learn: standardized code definition and clinical context for J1557; expected sites of service and service type; common billing considerations; and the types of benchmarks and policy updates that influence coverage and payment for intravenous immune globulin products. Data not available in the input will be noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ1557HCPCS Level IIimmune globulinintravenous infusionGammaplexinfusion therapymedical billingbiologic medication

Billing Code Overview

HCPCS Level II code J1557 describes an intravenous administration of immune globulin product Gammaplex, provided as a non-lyophilized (liquid) preparation, in a 500 mg unit. This code is used to report the medication itself rather than the infusion procedure.

Service Type: Intravenous immune globulin infusion (medication administration)

Typical Site of Service: Hospital outpatient infusion centers, physician office infusion suites, and ambulatory infusion clinics

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with an immune-mediated disorder such as primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia, or multifocal motor neuropathy who requires intravenous immune globulin replacement or immunomodulatory therapy. The patient arrives to an infusion center or hospital outpatient infusion suite with orders for J1557 (Immune globulin (GAMMAPLEX), IV, 500 mg per unit). The clinical workflow includes verification of the prescription and diagnosis, baseline vital signs and weight to calculate dose (commonly 0.4–2 g/kg depending on indication), review of prior infusion reactions and renal function, placement of IV access, premedication as ordered (antipyretic, antihistamine, corticosteroid), slow initiation of infusion with monitored titration per manufacturer and institutional protocol, documentation of lot numbers and total milligrams administered, and post-infusion observation for adverse events. Billing captures the medication units as J1557 with appropriate modifiers for circumstance (e.g., financial responsibility, administration setting, drug waste reporting), and the infusion administration services may be billed separately using appropriate CPT infusion administration codes in the outpatient or hospital setting. Typical sites of service are hospital outpatient infusion centers, physician office-based infusion suites, and ambulatory infusion centers. The typical patient scenario often includes serial infusions every 2–4 weeks for maintenance therapy or a multi-day course for induction based on the treating specialty (allergy/immunology, neurology, hematology).

Coding Specifications

Modifier	Description	When to Use

HCPCS Level II J1597: Glycopyrrolate Injection, 0.1 mg

HCPCS-J1800-PROPRANOLOL-INJECTION-UP-TO-1-MG

HCPCS Level II J1800: Propranolol HCl Injection, Up to 1 mg

HCPCS-J0696-CEFTRIAXONE-250MG-INJECTION

HCPCS J0696: Injection, ceftriaxone sodium, per 250 mg

HCPCS-J0137-INJECTION-ACETAMINOPHEN-HIKMA-10MG

HCPCS J0137: Injection, Acetaminophen (Hikma), 10 mg

HCPCS-J0169-EPINEPHRINE-INJECTION-0-1-MG

HCPCS J0169: Epinephrine Injection, 0.1 mg

HCPCS-J0641-LEVOLEUCOVORIN-INJECTION-05-MG

HCPCS J0641: Levoleucovorin Injection, 0.5 mg

HCPCS-J1631-HALOPERIDOL-DECANOATE-INJECTION-50MG

HCPCS J1631: Haloperidol Decanoate Injection, per 50 mg

HCPCS-J7186-ANTIHEMOPHILIC-FACTOR-VIII-VWF-COMPLEX-INJECTION

HCPCS J7186: Antihemophilic Factor VIII/vWF Complex Injection

HCPCS-J1741-IBUPROFEN-INJECTION-100MG

HCPCS J1741: Injection, Ibuprofen 100 mg

HCPCS-J1729-HYDROXYPROGESTERONE-CAPROATE-INJECTION-10MG

HCPCS J1729: Hydroxyprogesterone Caproate Injection, 10 mg

Showing 1–10 of 991

Taxonomy Code	Specialty	Notes
`207L00000X`	Allergy & Immunology	Common prescribers and overseers of IVIG therapy for immunodeficiency and autoimmune disease.
`2084N0400X`	Neurology	Manages IVIG for conditions such as CIDP and multifocal motor neuropathy.
`207RH0000X`	Hematology	Uses IVIG for immune thrombocytopenia and other hematologic immune disorders.
`363L00000X`	Infusion Nurse	Clinicians who administer and monitor IVIG infusions in outpatient settings.
`163W00000X`	Allergy/Immunology Nursing	Specialized nursing support for administration and patient education.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D83.9`	Common variable immunodeficiency, unspecified	IVIG `J1557` is used for immunoglobulin replacement in primary immunodeficiency disorders.
`D80.9`	Immunodeficiency disorder, unspecified	Indicates an immunodeficiency state that may require IVIG replacement therapy.
`G61.81`	Chronic inflammatory demyelinating polyneuropathy	IVIG is a standard immunomodulatory therapy for CIDP.
`D69.3`	Immune thrombocytopenic purpura	IVIG is used for rapid platelet elevation in immune thrombocytopenia.
`G51.0`	Bell's palsy	Occasionally IVIG is considered in specific immune-mediated neuropathies; inclusion is for related neuropathic immune indications.
`M35.3`	Polymyalgia rheumatica	IVIG is infrequently used; included to reflect select autoimmune inflammatory conditions where IVIG may be considered.
`M33.0`	Juvenile dermatomyositis	IVIG can be used as second-line immunomodulatory therapy in refractory inflammatory myopathies.
`M32.9`	Systemic lupus erythematosus, unspecified	IVIG can be used in certain severe or refractory autoimmune manifestations.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Used to report the initial infusion administration time when IVIG infusion starts in an outpatient setting.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)	Used to report additional infusion hours for prolonged IVIG administration beyond the first hour.
`96367`	Intravenous infusion, each additional sequential infusion of a new substance/drug	When a separate infusion of another agent is given sequentially during the same session.
`96413`	Chemotherapy administration, IV infusion technique, up to 1 hour, single or initial substance/drug	Occasionally used in institutional billing when facility requires chemotherapy infusion reporting conventions; generally not primary for IVIG.
`99070`	Supplies and materials (e.g., saline flushes, IV tubing) used during patient care not included in other codes	Used to capture non-drug supplies associated with infusion if payor allows separate supply reimbursement.
`36415`	Collection of venous blood by venipuncture	Performed before infusion for baseline labs such as renal function and CBC; may be billed when performed the same day.

`00`	No modifier	Rarely used; indicates no special modifier applies when payer requires explicit `00`.
`11`	State Medicaid agency review	When a state Medicaid program requires this modifier for local claims review.
`22`	Increased procedural services	When infusion required substantially greater resources or time than typical (document medical necessity).
`23`	Unusual anesthesia	Not typically used for `J1557`; only when unusual anesthesia is reported for concurrent procedures.
`52`	Reduced services	When the infusion was started but not completed as documented (partial dose given).
`53`	Discontinued procedure	If the infusion was discontinued due to adverse reaction and cannot be completed.
`78`	Return to the operating/procedure room	Not commonly applicable to outpatient IVIG infusions; used if patient returns to procedure room for complication.
`80`	Assistant at surgery	Not applicable to medication billing; included if surgical procedures are in same encounter.
`82`	Assistant not available	Rarely relevant; used when assistant surgeon was unavailable.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for Medicare reporting	When a qualifying non-physician practitioner provides the infusion under allowed rules for Medicare.
`GA`	Waiver of liability statement on file (no ABN)	When a voluntary payer liability waiver is on file for an item or service not typically covered.
`JW`	Drug discarded/not administered to any patient	To report wasted drug after opening single-use vial/bag when portion discarded.
`JZ`	Administered as billed, no waste	When the exact billed units were administered with no waste.
`QX`	CRNA services with direction by anesthesiologist	Not typically applicable; included if anesthesia team involved during infusion.
`QY`	Certified registered nurse anesthetist service with medical direction	As above; rarely used for outpatient IVIG infusions.

OpenPayer